This clinical care update describes a variety of viruses that can lead to respiratory illness. The viruses discussed include Influenza, Parainfluenza, Respiratory Syncytical Virus, Human Metapneumovirus, Rhinovirus, Adenovirus, and Enterovirus. These viruses are responsible for many unscheduled office visits and hospitalizations in both immunocompetent and immunocompromised individuals; people with asthma are often affected. Details presented in the article include viral characteristics, signs and symptoms, complications, diagnosis, treatment, and educational recommendations for asthma educators.
KarronRABelsheRBWrightPF. A live human parainfluenza type 3 vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J. 2003;22(5):394-405.
4.
Centers for Disease Control and Prevention. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. http://www.cdc.gov/hicpac/2007ip/2007ip_table2.html. Accessed November 17, 2010.
CunhaBA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am. 2004;18:141-155.
12.
Centers for Disease Control and Prevention. Pandemic Influenza Storybook: Personal Recollections From Survivors, Families and Friends. http://www.flu.gov/storybook/introduction/index.html. Accessed November 17, 2010.
KnipeDMHowleyPM eds. Fields Virology. 5th ed, Vols 1 and 2. Philadelphia, PA: Wolters Kluwer Health/Lippincott, Williams & Wilkins; 2007.
15.
SatoMWrightPF. Current status of vaccines for parainfluenza virus infections. Pediatr Infect Dis J. 2008;27(10 suppl):S123-S125.
16.
SigursNAljassimFKjellmanB. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045-1052.
17.
American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Clinical practice guideline: diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-1793.
18.
Palivizumaab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. The Impact-RSV Study Group. Pediatrics. 1998;102(3 pt 1):531-537.
19.
American Academy of Pediatrics. Policy statement: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-1701.
